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Abstract
Background: Benzalkonium chloride (BAC) is a common preservative used in ophthalmic
solutions. The aim of this study was to compare the cytotoxic effects of BAC-containing ophthalmic
solutions with a BAC-free ophthalmic solution using an organotypic 3-dimensional (3-D) corneal
epithelial model and to determine the effects of latanoprost ophthalmic solution and its BAC-
containing vehicle on corneal thickness in a monkey model.
Methods: The cytotoxicity of commercially available BAC-containing ophthalmic formulations of
latanoprost (0.02% BAC) and olopatadine (0.01% BAC) was compared to that of BAC-free
travoprost and saline in a corneal organotypic 3-D model using incubation times of 10 and 25
minutes. To compare the extent of differentiation of 3-D corneal cultures to monolayer
transformed human corneal epithelial (HCE-T) cell cultures, expression levels (mRNA and protein)
of the corneal markers epidermal growth factor receptor, transglutaminase 1 and involucrin were
quantified. Finally, latanoprost ophthalmic solution or its vehicle was administered at
suprapharmacologic doses (two 30 μL drops twice daily in 1 eye for 1 year) in monkey eyes, and
corneal pachymetry was performed at baseline and at weeks 4, 13, 26 and 52.
Results: In the 3-D corneal epithelial culture assays, there were no significant differences in
cytotoxicity between the BAC-containing latanoprost and olopatadine ophthalmic solutions and
BAC-free travoprost ophthalmic solution at either the 10- or 25-minute time points. The 3-D
cultures expressed higher levels of corneal epithelial markers than the HCE-T monolayers,
indicating a greater degree of differentiation. There were no significant differences between the
corneal thickness of monkey eyes treated with latanoprost ophthalmic solution or its vehicle (both
containing 0.02% BAC) and untreated eyes.
Conclusion: The lack of cytotoxicity demonstrated in 3-D corneal cultures and in monkey studies
suggests that the levels of BAC contained in ophthalmic solutions are not likely to cause significant
direct toxicity to epithelium of otherwise normal corneas.
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Unpreserved multiuse ocular solutions are at an increased
risk of microbial contamination [1] and can potentially
cause catastrophic consequences similar to those reported
with inadequately preserved contact lens solutions [2].
Because of its established efficacy compared to other
agents, the most common preservative used in topical
ocular solutions is benzalkonium chloride (BAC) [3].
Despite its long-standing clinical safety record supported
by extensive use in many pharmaceuticals and cosmetics,
the presence of BAC in topical solutions has been impli-
cated as a potential cause of corneal irritation, particularly
in situations where the corneal surface is compromised
such as that resulting from dry eye syndrome [4,5]. Ocular
hypotensive agents containing BAC have been reported to
have greater toxicity than BAC-free solutions when evalu-
ated in a transformed human corneal epithelial (HCE-T)
monolayer cell culture model [6]. However, this system
does not adequately duplicate the stratified nature of cor-
neal epithelium, which is better reflected in organotypic
3-dimensional (3-D) culturing conditions. Toxicity asso-
ciated with BAC-containing ophthalmic solutions has
also been demonstrated in rabbits [7-9], which are known
to be considerably more sensitive to corneal irritation [10]
and to have a longer duration of irritation [11] than
humans. The increased sensitivity may be due in part to
rabbits having an extremely low blink rate [12] and thin-
ner corneas [10] compared to humans.
Because of the limitations of the HCE-T monolayer and
rabbit models, the use of other in vitro model systems has
been explored. One such model is a commercially availa-
ble 3-D construct (SkinEthic Laboratories, Nice, France)
in which immortalized human corneal epithelial cells are
grown on an inert permeable polycarbonate insert and
cultivated at the air-liquid interface in a defined medium
[13-15]. These constructs have been shown to be histolog-
ically and ultrastructurally similar to the stratified cellular
organization of human corneal epithelium and to express
corneal-specific keratins [14]. Studies have shown a high
reliability and concordance of the 3-D constructs with in
vivo models in predicting irritancy of test compounds
[13,15,16].
The aim of this study was to compare the corneal cytotoxic
effects of the commercially available ophthalmic solu-
tions of latanoprost (containing 0.02% BAC) and travo-
prost (containing the preservative sofZia and no BAC),
both ocular hypotensive agents, and olopatadine ophthal-
mic solution, an antihistamine (containing 0.01% BAC),
using the 3-D model. Olopatadine was selected as a test
solution, due to its BAC content, to control for the mech-
anism of the pharmacologically active ingredient and its
usage in the treatment of ocular irritation associated with
allergies. Furthermore, the expression levels of basal and
suprabasal corneal epithelial markers were compared
between the 3-D and monolayer models to determine the
relative degrees of differentiation. Finally, we report the
findings of a 1-year study evaluating the effects of latano-
prost ophthalmic solution containing 0.02% BAC on cor-
neal thickness in monkeys receiving a daily
suprapharmacologic dose of latanoprost.
Methods
Cell cultures
Corneal epithelial 3-D culture inserts and the mainte-
nance medium (MCDB 153, 5 μg/mL insulin, 1.5 mM
CaCl2, 25 μg/mL gentamicin) were purchased from Ski-
nEthic Laboratories. The inserts were allowed to equili-
brate overnight in 6-well plates with 1 mL of the
maintenance medium at 37°C and 5% CO2 and then were
transferred into 300 μL of maintenance medium in a 24-
well plate prior to testing.
The HCE-T cell line 10.014 pRSV-T was obtained from the
American Type Culture Collection (Manassas, VA) and
grown to approximately 80% confluence in flasks coated
with collagen (PuroCol®; Inamed Biomaterials, Fremont,
CA), fibronectin, bovine serum albumin (Fraction V) and
hydrocortisone in a defined keratinocyte serum-free
medium (Invitrogen, Carlsbad, CA) according to the ven-
dor's protocol.
In vitro cytotoxicity assay
To demonstrate the sensitivity of the 3-D cultures, BAC at
concentrations of 0.005%, 0.01%, 0.025%, 0.05%,
0.075% and 0.1% and saponin at concentrations of
0.01%, 0.05%, 0.1%, 0.25% and 0.5% were incubated in
duplicate inserts for 60 minutes at 37°C. Statistical analy-
sis was not performed due to the limited number of repli-
cates. Once the sensitivity of the cultures was determined,
50 μL of test solutions was added to the 3-D cultures and
incubated at 37°C for 10 or 25 minutes. Test solutions
included latanoprost (Xalatan®) ophthalmic solution
0.005% (with 0.02% BAC: Pfizer Inc, New York, NY),
olopatadine (Patanol®) ophthalmic solution 0.1% (with
0.01% BAC: Alcon, Fort Worth, TX), travoprost (Travatan
Z®) ophthalmic solution 0.004% (with sofZia: Alcon, Fort
Worth, TX), 5% saponin (Sigma-Aldrich, St. Louis, MO),
70% methanol and normal saline (0.9% NaCl solution;
Baxter, Deerfield, IL). Rinsed inserts were then transferred
to a new 24-well plate containing 300 μL of 0.5 mg/mL
MTT (3-{4, 5-dimethylthiazol-2yl} 2, 5-diphenyltetrazo-
lium bromide; Sigma-Aldrich, St. Louis, MO) in mainte-
nance medium and incubated for 3 hours at 37°C. After
removal of the medium, isopropanol was added at room
temperature and plates were placed on an orbital shaker
for 90 minutes after which the absorbance of the extracts
was measured at 575 nm (SpectraMAX 190: Molecular
Devices, Sunnyvale, CA). Conditions were tested in tripli-
cate wells in three separate experiments. The absorbance
of each sample was normalized to the mean saline controlPage 2 of 7
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experiments (N = 9 samples) were combined for statistical
analysis using a 1-way analysis of variance.
Real-time quantitative reverse transcriptase-polymerase 
chain reaction assay
The 3-D cultures were rinsed with Dulbecco's phosphate-
buffered saline (DPBS) without calcium and magnesium
(Invitrogen), incubated with dispase at 37°C for 2 min-
utes and detached from the insert by gentle scraping with
forceps. The HCE-T monolayers were rinsed with DPBS
prior to harvesting in 700 uL of RLT buffer. RNA was
extracted using the RNeasy kit (Qiagen, Valencia, CA),
and RNA quality (as determined by 18s and 28s ribos-
omal RNA integrity) was assessed using the Lab-on-a-
Chip Nanochip (Agilent, Santa Clara, CA).
To perform the real-time quantitative reverse tran-
scriptase-polymerase chain reaction assay, 1 μg of RNA
was used as a template to generate cDNA with the Quant-
iTect Reverse Transcription kit (Qiagen). The relative
expression of epidermal growth factor receptor (EGFR)
was determined using 5 μM primers (Integrated DNA
Technologies, San Diego, CA) and fluorescent SYBR Green
dye (QuantiTect SYBR Green PCR kit, Qiagen) incorpora-
tion using the LightCycler® 2.0 System (Roche Applied Sci-
ences, Indianapolis, IN). The amplification was
performed in 20 μL reactions with optimized cycling and
annealing conditions. The specific primers and probes for
involucrin and transglutaminase 1 (TG1) were designed
with Roche's online Universal Probe Library (UPL) sys-
tem's Assay Design Center. Each 20 μL reaction mixture
contained 5 μL cDNA, 4 μL 5× qPCR Master Mix, 2 μL
each primer (5 μM) (Integrated DNA Technologies), 0.4
μL probe (10 μM) (Roche Applied Sciences) and 6.6 μL of
water. The samples were then loaded onto a 96-well plate
and amplified with an initial denaturation protocol of
95°C for 10 minutes followed by 45 cycles of 95°C for 10
seconds, 60°C for 30 seconds and 40°C for 30 seconds.
The expression of target genes was normalized to β-actin.
Standard curves were generated for each assay run. The
primers for EGFR were 5'-AATGCTTTCACAACATTTGC-3'
(forward) and 5'-ACAGGGCACACACAGATTAG-3'
(reverse). The primers for involucrin were 5'-GAAAGCA-
GAAAACCCAGAGC-3' (forward) and 5'-TAGCTGCT-
GATCCCTTTGTG-3' (reverse) (Roche UPL probe number
2). The primers for TG1 were 5'-CAAGAGACTAG-
CAGTGG-3' (forward) and 5'-AGGCCATTCTTGAT-
GGACTC-3' (reverse; UPL probe number 84). Statistical
comparisons were performed using a 1-tailed Student's t
test.
Western blot assay
Prior to lysis, the HCE-T monolayers were rinsed twice in
cold phosphate-buffered saline to remove the residual
medium; the maintenance medium was removed from
the 3-D inserts and the inserts were frozen at -80°C for 20
minutes. All samples were lysed in 100 μL of radioim-
mune precipitation assay buffer with 1× HALT protease
inhibitors (Pierce, Rockland, IL). Lysates were centrifuged
at 16,000 × g for 10 minutes at 4°C and the supernatants
were collected; protein concentrations were determined
using the bicinconinic acid protein assay (Pierce). Approx-
imately 40 μg of protein was heated to 95°C for 5 minutes
in NuPAGE 10× sample-reducing agent/LDS 4× Sample
Buffer (Invitrogen), electrophoretically separated with a
NuPAGE 4–12% Bis-Tris gel (Invitrogen) and transferred
to a 0.2 μm nitrocellulose membrane. After blocking in
fluorescent blocking buffer (Rockland Immunochemicals,
Gilbertsville, PA) for 1 hour at room temperature, the
membrane was incubated with primary antibodies over-
night at 4°C. Primary antibodies against corneal markers
included rabbit anti-human EGFR (1:1000; 100-401-149:
Rockland Immunochemicals), rabbit anti-human involu-
crin (1:50; BT-651: Biomedical Technologies Inc.,
Stoughton, MA) and mouse anti-human TG1 (1:50; BT-
621: Biomedical Technologies Inc.). To verify consistency
in protein loading, the membranes were incubated with
respective species-specific β-actin antibody (rabbit, cata-
log number 600-401-886, Rockland Immunochemicals;
or mouse, catalog number sc-47778, Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA). After three washes in 25
mM Tris/150 mM NaCl/0.1% Tween, the membranes
were probed with appropriate secondary infrared anti-
bodies (donkey anti-rabbit IgG, 611-730-127, or rabbit
anti-mouse IgG1, 610-430-040: Rockland Immunochem-
icals) for 1 hour at room temperature before visualizing
on the Odyssey infrared scanner (Li-Cor Biosciences, Lin-
coln, NE).
In vivo monkey pachymetry study
A chronic topical ocular toxicity study was conducted to
support the initial registration of latanoprost ophthalmic
solution. Cynomolgus monkeys (5/sex/group) were
treated for 1 year with topical ocular administration of
suprapharmacologic doses of latanoprost in a concen-
trated formulation specifically prepared for toxicity test-
ing (0.08%; 2–30 μL drops in 1 eye twice daily for a total
dose of 100 μg/day) or an equal volume of vehicle con-
taining 0.02% BAC. Study monkeys received latanoprost
in the right eye and its vehicle (containing 0.02% BAC) in
the left eye (2–30 μL drops twice daily for both treat-
ments) while control monkeys received no treatment in
the right eye and vehicle in the left eye. Corneal thickness
(pachymetry) was measured with an Ophthanasonic
Pachymeter (Teknar, St. Louis, MO) prior to dosing and at
weeks 4, 13, 26 and 52 of the dosing period. Mean
pachymetry values for the left vehicle-treated eye were
compared with those of the right eye (latanoprost-treated
or untreated). A Student's t test was used to determine the
statistical significance of the differences between treat-
ment conditions. Other data collected in the studyPage 3 of 7
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ophthalmic examinations and clinical signs. These studies
were conducted in accordance with the Association for
Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic and Visual Research and
were in compliance with Good Laboratory Practices.
Results
In vitro cytotoxicity assays
When the sensitivity of 3-D cultures to BAC-induced cyto-
toxicity was evaluated by incubating the inserts with a
range of concentrations of BAC for 60 minutes (Figure
1A), BAC concentrations comparable to those found in
commercial ocular solutions (<0.025%) showed no dif-
ferences in viability relative to the saline control. Statisti-
cal analysis was not performed due to the limited number
of replicates. At the highest BAC concentration tested
(0.1%), the viability was reduced to 66%. The positive
control (saponin at concentrations ranging from 0.01% to
0.5%) displayed extensive cytotoxicity (Figure 1B), with
viability as low as 6% relative to the saline control at the
high dose of 0.5%. These results established that the 3-D
cultures demonstrated dose-dependent toxicity of BAC.
The commercially available formulations of latanoprost,
olopatadine and travoprost were evaluated using incuba-
tion times of 10 or 25 minutes (Figure 2). With the 10-
minute incubation time, only the positive controls (meth-
anol and saponin) had a significant decrease in viability
compared to the saline control (p < 0.05). With the 25-
minute incubation time the difference in viability with
latanoprost ophthalmic solution was significantly lower
than with the saline control (p < 0.05); however, there
were no significant differences in viability with latano-
prost or olopatadine when compared with BAC-free travo-
prost (p > 0.05).
Corneal epithelial marker expression
The expression levels of three corneal epithelial markers
(EGFR, involucrin and TG1) were evaluated in both the 3-
D cell cultures and the HCE-T monolayer cultures. After
normalizing for β-actin expression, mRNA levels for all
three corneal epithelial markers were expressed at signifi-
cantly higher levels in the 3-D cultures than in the monol-
ayer cultures (Figure 3A). Specifically, when compared to
the monolayer cultures, the expression of mRNA levels in
the 3-D cultures were 3-fold (p < 0.001), 45-fold (p <
0.05) and 7-fold (p < 0.05) greater for EGFR, involucrin
and TG1 mRNA levels, respectively. The relative levels of
protein expression of the corneal epithelial markers as
determined by Western blot assay were consistent with
the mRNA expression, with the 3-D model demonstrating
higher levels of EGFR, involucrin and TG1 protein than
the monolayer cultures (Figure 3B).
Monkey pachymetry studies
In the 1-year monkey pachymetry studies, there was no
statistically significant difference (p > 0.4) in mean cor-
neal thickness between the eyes treated with BAC-contain-
ing vehicle and untreated eyes at any of the four time
points (Figure 4A). Similarly, in monkeys that were
administered suprapharmacologic doses of latanoprost
and vehicle (containing 0.02% BAC) of equal volume in
the other eye, there was no statistical difference (p > 0.5)
in the mean corneal thickness between the two treatments
at any point throughout the 52 weeks (Figure 4B). No his-
tological effects as assessed by light microscopy or clinical
Cytotoxicity of benzalkonium chloride (BAC) and saponin in 3-D c rneal epithelial culturesFigure 1
Cytotoxicity of benzalkonium chloride (BAC) and 
saponin in 3-D corneal epithelial cultures. The viability 
of the 3-D corneal inserts was determined after treatment 
with BAC (A) or saponin (B) for 60 minutes at 37°C. Data 
represent mean percent (± range) of the saline control.Page 4 of 7
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shown).
Discussion
Organotypic 3-D corneal epithelial cultures approximate
corneal epithelium, forming stratified layers approxi-
mately 60 μm thick and expressing corneal-specific kerat-
ins [14]. The layers consist of four to six cells, with
flattened superficial cells and several layers of wing cells;
ultrastructurally, the cells demonstrate surface microvilli,
tight junctions, numerous intercellular interdigitations
and desmosomes and a basement membrane [15]. The 3-
D cultures also have been shown to develop similar bar-
rier properties to corneal epithelium as measured by tran-
sepithelial electrical resistance [13,17].
The assays presented herein using 3-D corneal epithelial
cultures demonstrated no significant differences in cyto-
toxicity between the BAC-containing latanoprost and
olopatadine ophthalmic solutions and BAC-free travo-
prost ophthalmic solution at either of the time points (10
and 25 minutes) tested. Our results are in contrast to a
study demonstrating latanoprost toxicity in monolayer
cultures of HCE-T cells [6]. The same group reported that
up to 70% of the cells grown under these conditions died
in 5 minutes in their control, which was treated with cul-
ture medium alone [18]. However, HCE-T monolayer cul-
tures have been found to exhibit cytotoxicity when
exposed to concentrations of detergents well below those
affecting the viability of 3-D cultures [17]. Furthermore,
an ophthalmic solution that was nontoxic in rabbit cor-
neas and 3-D cultures was shown to cause breakage of cell
junctions and vacuolization in HCE-T monolayers [19].
These studies suggest that HCE-T monolayer cultures are
not appropriate for evaluating the cytotoxicity of ophthal-
mic compounds.
The difference in cytotoxicity between the HCE-T monol-
ayers and the 3-D cultures may reflect the extent of corneal
differentiation. We demonstrated that 3-D cultures
express significantly higher mRNA and protein levels of
three corneal epithelial markers (EGFR, involucrin and
TG1) compared to HCE-T monolayers. EGFR expression
has been demonstrated in the basal layers of human cor-
neal epithelium [20]. Involucrin has been observed in
suprabasal layers as is consistent with a role in differenti-
ation [20]. TG1 has been identified in the corneal epithe-
The effects of the ophthalmic solutions on 3-D human cor-neal pithelial cell viability reported as mean percent (± standard devia ion) of saline c n rolFigure 2
The effects of the ophthalmic solutions on 3-D 
human corneal epithelial cell viability reported as 
mean percent (± standard deviation) of saline con-
trol. Methanol (70%) and saponin (5%) were positive con-
trols and saline was a negative control. *p < 0.05 versus 
saline control. †p < 0.05 versus travoprost.
Expression of corneal epithelial gene markersFigure 3
Expression of corneal epithelial gene markers. (A) The 
relative mRNA expression levels of epidermal growth factor 
receptor (EGFR), involucrin and transglutaminase 1 (TG1) in 
3-D and transformed human corneal epithelial (HCE-T) mon-
olayer (ML) cultures as measured by real-time quantitative 
reverse transcriptase-polymerase chain reaction assay, nor-
malized to β-actin expression. (B) The relative protein 
expression levels of EGFR, involucrin and TG1 as determined 
by Western blot assay; β-actin was used as a loading control.Page 5 of 7
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keratocyte layer, where it is found in association with
fibrillin-containing microfibrils [21]. The relatively higher
expression level of EGFR in the monolayer system com-
pared to the other markers may reflect its expression in the
basal, less differentiated cell types.
The 3-D corneal cultures have been validated against the
Draize rabbit irritation assay [15,16]. In a multiple test-
site study, the 3-D model gave an 80% overall concord-
ance with rabbit irritancy data with 100% sensitivity [16].
A range in exposure times (10, 20, 30 and 60 minutes)
was investigated, with a 10-minute exposure found to be
the most predictive of 24-hour rabbit irritancy scores.
Cytotoxicity as measured by MTT reduction correlated
highly with both histopathological evaluation of the cul-
tures and the in vivo irritancy scores [16].
The duration of exposure of 3-D cultures to test com-
pounds in other studies has varied widely among
researchers, with some using 5-minute exposures [13,17]
and others using 20- and 60-minute exposures [19]. In
one study demonstrating toxicity of BAC in 3-D cultures
at concentrations as low as 0.005%, exposure times were
an extraordinarily long 6 and 24 hours [22]. In our assays,
exposure to BAC concentrations of 0.02% for 60 minutes
demonstrated no toxicity relative to the saline control.
Moreover, these durations far exceed those expected in
human eyes, for which mean ocular surface residence
times have been shown to be as low as 2.9 seconds [23].
In addition to the studies in the 3-D corneal cultures, we
conducted a 1-year corneal pachymetry study in monkeys
that demonstrated no effects of suprapharmacologic
doses (67 times the recommended clinical dose of latano-
prost and 4 times the associated dose of BAC) on corneal
thickness. Corneal pachymetry has been shown to be a
predictive measure of ocular irritation resulting in edema
in the corneal epithelium [24]. The absence of corneal
thickness changes, irritation or histological changes
implies a lack of a clinically significant or biologically
functional effect.
The results of our assays demonstrated no significant dif-
ferences in toxicity between commercially available BAC-
containing latanoprost and olopatadine ophthalmic solu-
tions and BAC-free travoprost ophthalmic solution using
3-D corneal epithelial cultures as an in vitro model of cor-
neal cytotoxicity. Although 3-D cultures have some regen-
erative capacity, they lack certain components of the
ocular surface that are involved in healing of corneal tis-
sues, including the tear film, the corneal stroma and
endothelium and the limbal vascular supply, which likely
increases their sensitivity to toxic injury [17]. Consistent
with the results of our study, Townley and Reilly [25]
recently reported that when patients experiencing ocular
dryness and irritation while receiving latanoprost with
BAC for at least 1 month were randomized to receive
latanoprost in one eye and travoprost without BAC in the
Corneal thickness measurements from 1-year monkey stud-iesFigure 4
Corneal thickness measurements from 1-year mon-
key studies. (A) Effect of topical administration of latano-
prost vehicle containing 0.2 mg/mL (0.02%) benzalkonium 
chloride on corneal thickness in monkeys. p > 0.4 for vehicle-
treated versus untreated eyes in both male and female mon-
keys at all time points. PD = predose. (B) Effect of the topical 
administration of suprapharmacologic doses of latanoprost 
(100 μg/day) on corneal thickness in monkeys. p > 0.5 for the 
vehicle-treated versus latanoprost-treated eyes in both male 
and female monkeys at all time points. PD = predose.Page 6 of 7
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in the eyes receiving travoprost (p = 0.025). In addition,
the eyes receiving BAC-free travoprost showed a trend
toward more dryness.
Conclusion
The lack of cytotoxicity demonstrated here using 3-D cor-
neal cultures combined with the monkey pachymetry data
suggest that the levels of BAC in BAC-containing ophthal-
mic solutions do not likely cause significant direct toxicity
to the epithelium of otherwise normal corneas. Data sup-
porting the safety of BAC are contained in documentation
submitted to regulatory agencies in the support of both
prescription and nonprescription (over-the-counter)
products in ophthalmic, otic and nasal preparations for
several decades. The results of this study support the
present acceptable safety profile for such agents.
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